|
Please
download and print the PDF file below:
|
|
|
|
Terri L. Crawford-Bonadio, RN, CNN
|
Terri L. Crawford-Bonadio, RN, CNN, is
Global Director, PDServe, Fresenius Medical Care
North America, Lexington, MA. She is a member
of ANNA’s Greater Charlotte Chapter and
Peritoneal Dialysis Special Interest Group. |
|
Jose A. Diaz-Buxo, MD, FACP |
Jose A. Diaz-Buxo, MD, FACP, is Senior Vice
President, Home Therapies Development, Fresenius
Medical Care, Lexington, MA. |
The composition of peritoneal dialysis solutions to a great extent, determine their effectiveness
and safety. Many of the factors that determine the bioincompatibility of peritoneal
dialysis fluids have been recently identified. This knowledge is essential to modify
the manufacturing processes and in the quest for more biocompatible solutions. A
description of the available peritoneal dialysis fluids in the United States and a comparison
of their formulations are provided.
|
|
CE
RELATED INFORMATION |
|
This
offering for 1.5 contact
hours is being provided by
the
American
Nephrology Nurses Association
(ANNA), which
is accredited as a provider
and approver of continuing
education in nursing by
the American Nurses
Credentialing Center-Commission
on Accreditation (ANCCCOA).
This educational activity
is approved by most states
and specialty organizations
that recognize the ANCC-COA
accreditation process. ANNA
is an approved provider of
continuing education in nursing
by the California Board of
Registered Nursing, BRN Provider
No. 00910.
|
|
Goal:
To describe the similarities and differences in conventional and new peritoneal dialysis
solutions in terms of biocompatibility, osmotic agents, and buffer bases.
Objectives:
1.
Discuss the main strategies that have been employed to improve the characteristics
of peritoneal dialysis solutions.
2. Describe the osmotic agents and buffer bases currently used in peritoneal dialysis
solutions in terms of their effectiveness, potential uses, and side effects.
3. Compare various peritoneal dialysis solutions as to strengths, pH, glucose
degradation products (GDPs), and availability.
|
AUTHOR DISCLOSURE
STATEMENT |
Terri Crawford-Bonadio has
no conflicts of interest to disclose.
Jose Diaz-Buxo has
no conflicts of interest to disclose.
|
ANNA and HDCN CE POLICY STATEMENTS |
The CE policy and disclosure statements of the American Nephrology
Nurses' Association are given in detail on the Symposium
Home Page. The CE policy statements of HDCN are listed on
this page. |